Patient Selection
The database was reviewed to identify patients who underwent attempted or successful balloon angioplasty for the treatment of SAH-induced vasospasm. Patients treated with tip-mounted balloon catheters (Interventional Therapeutics Corp. or Endeavor [Boston Scientific Corporation, Natick, MA]) were excluded. Patients treated with vasodilators only were excluded, unless balloon angioplasty was also attempted during the same procedure. Patients presenting with unsecured aneurysms and severe vasospasm treated during the endovascular aneurysm obliteration procedure were also excluded.
Endovascular Vasospasm Treatment
At our institution, all patients with suspected symptomatic cerebral vasospasm undergo catheter angiography. Transcranial Doppler ultrasound is not used for screening. Depending on the clinical situation and severity of symptoms, hypervolemic hypertensive therapy may be instituted prior to the angiographic diagnosis of vasospasm.
A No. 5 or 6 French arterial sheath is used for all procedures. Diagnostic angiography is performed using No. 5 French diagnostic catheters. Both common carotid arteries and a VA are injected selectively, and the images are compared to those from the initial angiographic study performed at the time of SAH diagnosis. Vasospasm is subjectively graded as mild, moderate, or severe. 17 After vasospasm is angiographically diagnosed, a choice is made between medical and endovascular treatment. This decision is reached through discussion among the attending interventional neuroradiologist, neurosurgeon, and neurointensivist. In general, if moderate or severe vasospasm is present in a vessel referable to the patient's symptoms and the condition is amenable to angioplasty (that is, involved vessels are accessible by endovascular means), balloon angioplasty is pursued. Attempts are made to treat all accessible vessels that are affected by moderate to severe vasospasm, even if symptoms are clearly referable to a single vessel territory. Vasodilators are used for the treatment of vessels that cannot be treated with balloons. 23 General anesthesia is often used, depending on the amount of patient movement, intubation status, and the perceived technical difficulty of balloon angioplasty. Heparin is administered systemically to increase the activated clotting time to twice the patient's baseline measurement, unless there is a significant contraindication. The recent or remote placement of an EVD is not considered a contraindication to heparinization. Hypervolemic hypertensive therapy is maintained if it was instituted prior to the procedure. 1, 18 A No. 5 French guide catheter or diagnostic catheter is advanced into the target ICA or VA. After placement of the catheter, vasodilators are sometimes infused prior to angioplasty if blood flow is particularly slow. Papaverine hydrochloride was used in most of the cases in this series. 16 Verapamil has been used more recently after concerns regarding the toxicity of papaverine were raised. 1, 2, 14, 15, 24 A variety of balloon catheters were employed (see Table 3 ). The choice of balloon is at the discretion of the operator.
As a result of current device availability and performance, in the majority of the cases and all recent procedures, we have used the Hyperglide balloon (EV3 Inc., Plymouth, MN). This balloon has a low profile and can be advanced through a No. 5 French diagnostic catheter. The balloon is tested and prepared with a 50% contrast solution prior to placement, and it is advanced over a wire that occludes the distal tip and allows balloon inflation. Selection of vessels is performed using fluoroscopic landmarks, such as bone or aneurysm clips or coils, or with roadmapping techniques. After proper placement through the area of stenosis, the balloon is inflated and immediately deflated as soon as the target diameter is reached. The balloon has a maximum inflated diameter of 4 mm. Angioplasty of vessels smaller than 4 mm is accomplished with careful subtotal inflation. Angioplasty is not attempted for vessels distal to the proximal segments of the MCA (M 1 ), ACA (A 1 ), or posterior cerebral artery (P 1 ).
Control angiography is performed after angioplasty to assess treatment results, distal spasm, and thromboembolic complications. Vasodilator infusions through the guide catheter or a microcatheter are frequently performed to treat residual distal spasm. At the conclusion of the procedure, the catheter is removed and systemic heparin administration is either discontinued or reversed. The sheath is removed at that time or several hours later in the intensive care unit, and hemostasis is achieved through manual compression.
Chart Review
The quality assurance database included each patient's name, sex, and date of birth, as well as the date of the procedure, names of the devices employed, and information on the occurrence of any procedural complications. The medical records and angiographic reports were obtained for patients who met the inclusion criteria for the present study. Information gathered for this study included the date of SAH (if known), cause of SAH, Hunt and Hess grade, Fisher grade, aneurysm location (in cases of aneurysmal SAH), mode of aneurysm therapy, date of endovascular therapy for vasospasm, details of the endovascular procedure, and whether an EVD was placed or other neurosurgical procedure was performed prior to vasospasm treatment.
Procedural details included the vessels involved by moderate to severe vasospasm, the number of these vessels targeted for balloon angioplasty, and the number in which balloon angioplasty successfully restored vessel diameter. We considered the distal ICA, the VA and BA, the M 1 segment, and the A 1 segment to be amenable to angioplasty, unless otherwise stated. Reasons given in the reports for not treating accessible vessels in severe spasm were recorded. The use of general anesthesia and heparin was recorded, as was the adjunctive use of vasodilators. Any procedural complications were recorded.
Durability of Balloon Angioplasty
We reviewed the reports from all follow-up angiograms or repeat balloon angioplasty procedures performed within 2 weeks after the initial angioplasty procedure. 19 The presence of moderate or severe vasospasm at sites that had been previously treated was recorded.
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Safety and Technical Efficacy
The primary safety measurements in this study were the occurrence of vessel rupture from balloon inflation or wire perforation and thromboembolic complications. Other complications were also recorded, including any evidence of arterial injury (dissection) or groin hematoma requiring transfusion or surgical repair. Reports from postprocedural CT scans were reviewed for any evidence of intracerebral hemorrhage along the EVD track. The primary technical end point was successful treatment of accessible vessels.
Data Analysis
All data were recorded on an Excel (Microsoft Corp., Redmond, WA) spreadsheet for analysis. Complication rates were reported as a percentage of procedures performed. Technical success rates were reported as a percentage of target vessels involved by vasospasm.
Results

Demographic Characteristics
Demographic characteristics of the patients are summarized in Table 1 . Seventy-five patients (22 men and 53 women) underwent 85 balloon angioplasty procedures using over-the-wire balloons between June 1995 and June 2006. Their mean age was 47 years (range 16-73 years). The mean Hunt and Hess grade was III. The cause of SAH was aneurysmal in 69 patients (see Table 2 for locations). In the remaining six patients, the cause of SAH was traumatic carotid cavernous fistula (two patients), arteriovenous malformation (one patient), or unknown (three patients). Forty-six of the patients with ruptured aneurysms underwent craniotomy for clip placement and 23 were treated endovascularly with detachable coils. One of the aneurysms was treated with both coil and clip placement.
Both traumatic fistulas were treated with endovascular coil placement, and one was also treated with a detachable balloon. Forty-two patients underwent EVD placement before endovascular intervention for vasospasm.
Procedural Details
Characteristics of the angioplasty procedures are summarized in Table 3 . Moderate or severe vasospasm was identified on diagnostic angiography at a mean of 8 days (range 3-24 days) after SAH in these 75 patients. Thirty-
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Over-the-wire balloons for SAH-induced cerebral vasospasm 3 two endovascular procedures were performed under general anesthesia. In 27 cases, an endotracheal tube was already in place at the time of the procedure; in five others an endotracheal tube was inserted to provide general anesthesia for the endovascular procedure. Adjunctive vasodilators were administered in 44 procedures (papaverine in 23, verapamil in 21). Angioplasty was attempted in 41 of these 89 vessels and was successful in only 14 (34%). The balloon could not be advanced over the wire in 19 of the 27 unsuccessful attempts. Reasons given for treatment failure or for no attempt at treatment having been made are given in Table 5 .
Technical Efficacy
Procedural Safety
No instance of vessel rupture or perforation was identified in this study, but thromboembolic events occurred in four patients (Table 6 ). Filling defects were identified in the distal territory of the ICA on postprocedural angiography in three patients. These defects led to large MCA infarctions in two patients despite attempted thrombolysis. Both patients had been treated with systemic heparin. One patient who was not treated with systemic heparin had a single small distal branch occlusion with no clinical consequence. The fourth patient probably suffered an embolic occlusion of the distal ICA on placement of the guide catheter prior to receiving systemic heparin. Severe spasm was evident on the diagnostic angiogram. After a guide catheter was placed in the ICA, no blood flow was found beyond the ophthalmic artery. Angioplasty and thrombolytic therapy did not restore patency, and the patient suffered a large hemispheric infarction. One patient suffered a retroperitoneal hemorrhage. No intracerebral hemorrhages were identified along the path of the EVD catheter in the 42 patients who required placement of an EVD before their angioplasty procedure. Table 4 summarizes data pertaining to the recurrence of vasospasm identified on follow-up angiography, which was performed in 38 of the 75 patients. Ten (26%) of these 38 patients ultimately required a second balloon angioplasty procedure for the treatment of vasospasm. The risk of recurrence of moderate-to-severe vasospasm in a previously treated territory was 12.9% (15 of 116 vessels) in these patients who underwent repeat angiography. This risk A. Terry, et al. 
Treatment Durability
Discussion
Demographic Characteristics
We reviewed our experience in 75 cases of symptomatic cerebral vasospasm treated with balloon angioplasty using new over-the-wire, low-pressure balloons. We included, in addition to patients with known aneurysmal SAH, six patients with nonaneurysmal SAH, based on the rationale that this is a study of angioplasty to treat symptomatic vasospasm, irrespective of the origin of the hemorrhage.
In general, our results reflect the preponderance of data for vessels in the anterior cerebral circulation. Not only was severe vasospasm less frequent in the posterior circulation (VA and BA), it was also successfully treated more often and persisted less often. This may be due to aneurysm location; most aneurysms occurred in the anterior circulation in our study (56 [81.2%] of 69 cases). The grading of vasospasm as moderate or severe is subjective; we chose to include only cases with these grades because we wanted to identify patients who had vasospasm that was severe enough for treatment to be considered (vasospasm classified as mild is not usually treated).
Technical Efficacy
Our research demonstrates that balloon angioplasty has a high rate of technical efficacy in most arterial territories treated, with a success rate of greater than 90% in the distal ICA and the M 1 segment. However, balloon angioplasty of the proximal ACA remains a technical challenge, with a treatment success rate of only 34%. Moreover, despite significant rates of vasospasm in this territory, angioplasty was often not attempted due to technical difficulties, most prominently an unfavorable angle that prevented advancement of the balloon catheter. In some of these cases, vasospasm resolved after the administration of vasodilator medication, which provides less durable results than angioplasty. Treatment failure and technical inability to treat this territory remain important problems that may be resolved in the future by improved balloon design. The Hyperglide balloon catheter has a diameter of 4 mm, which exceeds the average diameter of the A 1 segment (2-3 mm), increasing the risk of perforation during treatment. Smaller balloon diameters should improve safety and ability to access the A 1 segment as well as more distal segments in other territories, potentially including A 2 and M 2 . In addition, better tracking will improve the ability to negotiate the sharp angle at the origin of the ACA. 9 Although in our study the rate of technical success was high for most territories, our findings may represent an overestimate of technical success due to selection bias: easily treatable territories are more likely to be treated. 11 Thus the relatively low success rate for A 1 may still be artificially inflated by the fact that patients with tortuosity or congenitally hypoplastic A 1 segments were not treated due to safety concerns. In addition, some patients with tortuous M 1 segments or significant carotid atherosclerosis were treated with vasodilator medication rather than angioplasty, causing a transient improvement in the vasospasm in that territory without necessarily producing durable results. Because follow-up angiography was performed in only 38 cases (50.7%), it is difficult to assess the long-term efficacy of treatment. The temporary effects of vasodilator treatment are well recognized. 5, 6, 13, 14 Procedural Safety Our rate of serious complications was quite low, with no instances of vessel rupture or perforation, four thromboembolic events directly attributable to the angioplasty procedure (4.7%), one retroperitoneal hematoma (1.2%), and no EVD track hemorrhage. Minor complications (transient hypotension, sheath dislodgment, prolonged bleeding at the puncture site) occurred in only two patients.
The complication rate may be artificially low for two reasons. First, the computerized record may be incomplete (especially before 2001), failing to reveal minor complications or delayed recognition of thromboembolic events attributable to the procedure. Second, it is often difficult to determine whether unfavorable outcomes such as new infarctions are due to thromboembolic complications of angioplasty or problems inherent to the disease process, such as ongoing vasospasm. 3, 22 As with technical efficacy, prospective studies are needed to assess complication rates more accurately and ensure that specific complications are recognized and recorded in a timely manner.
We observed no EVD track hemorrhages on the postprocedure CT scans. Although a CT scan of the head was not obtained in all patients within the first few days after the procedure, the absence of EVD track hemorrhages in those patients in whom CT scans were obtained is not a surprising finding, considering that most EVDs were placed shortly after hospital admission, several days before the patient's first angioplasty procedure. A recent review of aneurysm coil placement procedures performed soon after EVD placement for SAH found no difference in the risk of EVD track hemorrhage between 117 patients who were treated with coil placement and systemic heparin and 251 patients with SAH who did not receive systemic heparin or undergo coil placement.
found during the diagnostic stage. Because the main argument for the use of heparin during angioplasty revolves around prevention of thromboembolism and two of the five patients with thromboembolic complications apparently were not given adequate heparin treatment, it appears that the routine use of heparin as systemic anticoagulation therapy during angioplasty is more than justified.
Treatment Durability
We found that in some cases, vasospasm did recur after balloon angioplasty (15 [12. 9%] of 116 treated vessels that were reexamined). This phenomenon was most notable in the A 1 territory. As mentioned, this finding may reflect inadequate angioplasty due to technical or safety reasons (for example, concern about vessel perforation or tortuosity) or it may reflect recurrence after successful angioplasty. Our recurrence rate may be artificially high due to the fact that only half of the patients had follow-up angiographic examinations. These patients probably had symptoms indicative of recurrent or persistent vasospasm, and 10 (26.3%) of these 38 patients eventually required a second balloon angioplasty procedure. Patients who did well clinically would not be as likely to undergo followup angiographic examination and therefore would not have been included in our results. Therefore, our estimate probably represents an upper limit for the risk of recurrent vasospasm.
More information about the relationship between procedural safety/technical efficacy and clinical outcomes would be welcome. We chose not to take this approach in our study because of the difficulty in determining the patient's initial clinical grade and long-term outcome from the medical record and also because of the lack of a straightforward relationship between the endovascular interventions and the patient's clinical condition. Variables (such as the severity of the initial hemorrhage, medical comorbidities, efficacy of concurrent hemodynamic therapy, and the natural progression of the disease process) may influence outcome independent of endovascular interventions. 3, 22 However, we did record data on the patients' estimated neurological condition on discharge, which may be used in future studies.
Conclusions
In sum, our research demonstrates a high rate of technical efficacy for balloon angioplasty except in the proximal anterior cerebral artery, where the lower success rate may be ascribed to both failure to treat and unsuccessful treatment. In the future, improved balloon technology should greatly enhance our ability to treat this vessel territory. Complication rates were low, in particular with respect to vessel rupture and intracerebral hemorrhage along the EVD track, although prospective studies are needed for more accurate assessment. The primary risk of the procedure relates to thromboembolic complications, and patients should be routinely treated with systemic heparin administration. Finally, vasospasm did occasionally recur at sites previously treated using angioplasty.
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